ENTITY
BeiGene

BeiGene (6160 HK)

322
Analysis
Health CareChina
BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.
more
bullishBeiGene
12 Aug 2024 08:55

BeiGene (6160.HK/BGNE.US) 24Q2 - It Is Time to Open a New Chapter in China's Pharmaceutical Industry

​BeiGene's strong Q2 results make breakeven possible in Q4.BRUKINSA may surpass Calquence in sales next year.BeiGene is a new king in China's...

Logo
263 Views
Share
bullishBeiGene
10 Aug 2024 05:54Broker

BeiGene (BGNE US) - Sales Exceeding Expectations and Achieving Non-GAAP Profitability

Product sales continued beating expectations. In 2Q24, BeiGene recorded total product sales of US$921mn (+23% QoQ, +66% YoY).

Logo
317 Views
Share
04 Nov 2024 20:48

2023 High Conviction Update: Revolution Medicines, Time To Take Profits?

I remove Revolution Medicines stock from my high conviction list of ideas due to achieving a $55.00 price target and full valuation relative to peers.

Logo
74 Views
Share
bullishBeiGene
13 May 2024 08:55

BeiGene (6160.HK/​BGNE.US/688235.CH) 24Q1- A Breakeven Point Is on the Horizon, but It Is Not Stable

​BeiGene's high product revenue growth in 24Q1 narrowed net loss, with potential for breakeven in 24Q4.This is an affirmation for BeiGene....

Logo
271 Views
Share
bullishBeiGene
10 May 2024 18:57Broker

BeiGene (BGNE US) - Consistently Exceeding Expectations

Product sales continued beating expectation. In 1Q24, BeiGene recorded total product sales of US$747mn (+18% QoQ, +82% YoY), representing 25.7% of...

Logo
392 Views
Share
x